Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190)
Hong Kong · Delayed Price · Currency is HKD 21.60
+0.10 (0.47%)
Sep 30, 2026, 4:08 PM HKT
HKG:2190 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,208 | 1,057 | 782.48 | 527.75 | 334.09 | 177.91 | |
Revenue Growth | 34.40% | 35.15% | 48.27% | 57.97% | 87.78% | 543.88% |
Cost of Revenue | 323.85 | 294.57 | 222.58 | 142.77 | 81.42 | 46.03 |
Gross Profit | 883.7 | 762.92 | 559.9 | 384.99 | 252.67 | 131.88 |
Selling, General & Admin | 354.32 | 315.88 | 265.76 | 277.92 | 249.47 | 195.87 |
Research & Development | 231.56 | 246.78 | 233.23 | 261.01 | 233.46 | 168.1 |
Other Operating Expenses | 1.2 | 1.16 | 1.36 | 1.6 | -6.78 | -13.94 |
Operating Expenses | 587.06 | 563.81 | 500.39 | 540.54 | 476.18 | 350.05 |
Operating Income | 296.64 | 199.11 | 59.51 | -155.55 | -223.51 | -218.17 |
Interest Expense | -2.73 | -1.02 | -2.18 | -1.25 | -0.72 | -0.31 |
Interest & Investment Income | 50.37 | 59.19 | 67.35 | 79.04 | 95.57 | 13.09 |
Earnings From Equity Investments | - | - | -1.1 | - | - | - |
Currency Exchange Gain (Loss) | -5.88 | -7.16 | 1.51 | -0.26 | 19.63 | -8.28 |
Other Non Operating Income (Expenses) | -18.7 | -12.64 | 11.43 | 8.4 | - | - |
EBT Excluding Unusual Items | 319.7 | 237.48 | 136.51 | -69.63 | -109.04 | -213.66 |
Gain (Loss) on Sale of Investments | 1.35 | -0.65 | -36.21 | -8.51 | 4.81 | 13.95 |
Gain (Loss) on Sale of Assets | 0.07 | -0.09 | -0.05 | -0.59 | -9.32 | 0.02 |
Pretax Income | 319.57 | 236.74 | 100.26 | -78.73 | -113.56 | -199.69 |
Income Tax Expense | 17.29 | -7.63 | - | - | - | - |
Net Income | 304.88 | 244.37 | 100.26 | -78.73 | -113.56 | -199.69 |
Net Income to Common | 304.88 | 244.37 | 100.26 | -78.73 | -113.56 | -199.69 |
Net Income Growth | 99.80% | 143.75% | - | - | - | - |
Shares Outstanding (Basic) | 319 | 320 | 323 | 329 | 330 | 295 |
Shares Outstanding (Diluted) | 321 | 324 | 328 | 329 | 330 | 295 |
Shares Change | -1.89% | -1.34% | -0.22% | -0.51% | 12.15% | 51.26% |
EPS (Basic) | 0.96 | 0.76 | 0.31 | -0.24 | -0.34 | -0.68 |
EPS (Diluted) | 0.95 | 0.76 | 0.31 | -0.24 | -0.34 | -0.68 |
EPS Growth | 105.48% | 147.04% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 371.85 | 273.64 | -17.26 | -92.48 | -226.06 | -194.32 |
Free Cash Flow Per Share | 1.16 | 0.85 | -0.05 | -0.28 | -0.68 | -0.66 |
Dividend Per Share | 0.220 | 0.220 | 0.100 | - | - | - |
Dividend Growth | 120.00% | 120.00% | - | - | - | - |
Gross Margin | 73.18% | 72.14% | 71.55% | 72.95% | 75.63% | 74.13% |
Operating Margin | 24.57% | 18.83% | 7.61% | -29.48% | -66.90% | -122.63% |
Profit Margin | 25.25% | 23.11% | 12.81% | -14.92% | -33.99% | -112.24% |
Free Cash Flow Margin | 30.79% | 25.88% | -2.21% | -17.52% | -67.66% | -109.22% |
EBITDA | 331.42 | 232.21 | 91.69 | -126.66 | -203.47 | -208.49 |
EBITDA Margin | 27.45% | 21.96% | 11.72% | -24.00% | -60.90% | -117.18% |
D&A For EBITDA | 34.78 | 33.1 | 32.18 | 28.9 | 20.04 | 9.68 |
EBIT | 296.64 | 199.11 | 59.51 | -155.55 | -223.51 | -218.17 |
EBIT Margin | 24.57% | 18.83% | 7.61% | -29.48% | -66.90% | -122.63% |